- 02 apr.- 10:39

GN Hearing partners with hearing care professionals to launch a game-changing telehealth solution: New innovative at-home access to hearing aids and care

Business Wire.

People can now get hearing aids from the comfort and safety of home with ReSound Assist Live video consultations from their hearing care professional. 

  • In the context of COVID-19, the accelerated launch of ReSound Assist Live enables a new, ground-breaking way to access hearing care, reducing the need for in-office visits at a time when older, more vulnerable populations are advised to stay at home.
  • Cutting-edge telehealth allows for the broadest range of at-home hearing care services for those with hearing loss, keeping them connected to family and community. 
  • The new solutions will allow people to take a hearing test, currently in the US, in a drive-through setting or at home, buy and receive hearing aids and have them adjusted, without having to enter the clinic.
- 02 apr.- 08:16

RELIEF THERAPEUTICS Holding SA Announces the Closing of its Share Exchange Agreement with Sonnet BioTherapeutics, Inc. for the Divestment of its wholly-owned Subsidiary Relief Therapeutics SA

Business Wire.
  • RELIEF THERAPEUTICS Holding SA (SIX:RLF, “Relief Holding”) announces the closing of the binding Share Exchange Agreement (“SEA”) for the acquisition by Sonnet BioTherapeutics, Inc. (“Sonnet”), now a subsidiary of Sonnet BioTherapeutics Holdings, Inc. (Nasdaq:SONN, "Sonnet Holdings") of Relief Therapeutics SA (“Relief SA”), a subsidiary of Relief Holding signed August 12, 2019
  • Closing was subject to fulfillment by Sonnet of certain conditions precedent which have now been satisfied
  • Based on the SEA terms, Sonnet paid to Relief Holding shares of its common stock that converted into 757,933 shares of listed Sonnet Holdings common stock
  • Sonnet will pursue its already initiated commitment to fund the clinical development of Relief SA’s asset, Atexakin Alfa (low dose formulation of Interleukin-6, IL-6, now “SON-080”), for the treatment of Peripheral Neuropathies focusing primarily on Chemotherapy-Induced Peripheral Neuropathy (CIPN)
  • Relief Holding will in turn focus its resources on the rapid development of Aviptadil for the consequences of COVID-19 infections in particular Acute Respiratory Distress Syndrome (“ARDS”)
- 02 apr.- 07:35

As Part of a Global Partnership with Nestlé Health Science, VALBIOTIS Initiates the Pivotal Late Stage Development Phase of TOTUM-63, a Plant-Derived Active Substance With Clinically Demonstrated Metabolic Health Benefits in People With Prediabetes

Business Wire.
  • This last pivotal trial (REVERSE-IT), has been designed jointly with Nestlé Health Science’s teams and will be entirely funded by the partnership agreement;
  • This international trial will include 600 participants and should be launched before mid-2020;
  • Its first objective is to confirm the positive results of the Phase II clinical trial on fasting blood sugar levels, a well-established risk factor for developing Type 2 Diabetes, to obtain strong health claims;
  • The trial aims to include a broad population with altered glucose metabolism, spanning from elevated fasting glucose to early (yet untreated) Type 2 Diabetes.
- 02 apr.- 07:00

Athora Completes Acquisition of VIVAT and Provides a Capital Injection of €400 Million

Business Wire.
  • VIVAT’s life and asset management businesses are now part of Athora, a leading life insurance and reinsurance group in Europe
  • Athora has sold 100% of the shares of VIVAT Non-life to NN Group, via a back-to-back transaction
  • Successful completion of the transaction establishes Athora as the leading consolidator in the European life insurance market
  • Athora fully supports VIVAT’s efforts to better fulfil customer needs through its leading brands Zwitserleven, Reaal and ACTIAM
  • All current and future insurance policies from VIVAT’s subsidiaries will stay in the Netherlands and remain under Dutch regulation
  • Broad set of measures introduced to strengthen VIVAT’s capital position, including a €400 million injection of new equity capital
  • To reduce VIVAT’s leverage, Athora is supportive of VIVAT’s tender for its senior debt as announced today
  • Athora will ensure VIVAT operates in compliance with the full version of the Dutch Large Company Regime
  • Combined, Athora group will have approximately €70 billion of consolidated assets and approximately 3 million customers
  • Athora has €4 billion of total equity capital following its capital raises in 2017 and 2020
  • Following closing and the injection of capital into VIVAT, Athora will have close to €1 billion of committed equity available to support Athora, VIVAT and existing subsidiaries
- 02 apr.- 04:00

MHPS: World’s Most Efficient Power Plant Is Synced to the Grid and Operating at Full Load, Ahead of Schedule

Business Wire.

-- T-Point 2 Validation Facility Features the Enhanced JAC Power Train --

  • Facility will validate the performance and reliability of the 1650°C-class JAC gas turbine, the most efficient heavy-duty gas turbine in the market
  • Poised to become the world’s first autonomous combined cycle power plant featuring MHPS-TOMONI® suite of intelligent digital solutions

 

- 01 apr.- 11:50

Al via dal 1 aprile i .eu Web Awards 2020! Non perdeteveli!

Business Wire.

La raccolta delle nomination per la settima edizione dei .eu Web Awards è ora aperta e proseguirà fino al 5 agosto. Assicuratevi di votare per il vostro sito web preferito in ciascuna delle cinque categorie.

Video Economia

Vai alla rubrica Risparmio e Investimenti
Vai al sito: ANSA Professioni


Vai al sito: L'Agenda Economica Finanziaria e Rassegna Stampa dell'ANSA
Vai alla rubrica: Pianeta Camere
Vai alla rubrica: Agrimercati
Vai alla rubrica: PMI

Criptovalute news


Modifica consenso Cookie